Rituximab Selectively Suppresses Specific Islet Antibodies
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: The TrialNet Study Group evaluated rituximab, a B-cell–depleting monoclonal antibody, for its effect in new-onset patients with type 1A diabetes. Rituximab decreased the loss of C-peptide over the first year of follow-up and markedly depleted B lymphocytes for 6 months after administration. This article analyzes the specific effect of rituximab on multiple islet autoantibodies. RESEARCH DESIGN AND METHODS: A total of 87 patients between the ages of 8 and 40 years received either rituximab or a placebo infusion weekly for four doses close to the onset of diabetes. Autoantibodies to insulin (IAAs), GAD65 (GADAs), insulinoma-associated protein 2 (IA2As), and ZnT8 (ZnT8As) were measured with radioimmunoassays. The primary outcome for this autoantibody analysis was the mean level of autoantibodies during follow-up. RESULTS: Rituximab markedly suppressed IAAs compared with the placebo injection but had a much smaller effect on GADAs, IA2As, and ZnT8As. A total of 40% (19 of 48) of rituximab-treated patients who were IAA positive became IAA negative versus 0 of 29 placebo-treated patients (P < 0.0001). In the subgroup (n = 6) treated within 50 days of diabetes, IAAs were markedly suppressed by rituximab in all patients for 1 year and for four patients as long as 3 years despite continuing insulin therapy. Independent of rituximab treatment, the mean level of IAAs at study entry was markedly lower (P = 0.035) for patients who maintained C-peptide levels during the first year of follow-up in both rituximab-treated and placebo groups. CONCLUSIONS: A single course of rituximab differentially suppresses IAAs, clearly blocking IAAs for >1 year in insulin-treated patients. For the patients receiving insulin for >2 weeks prior to rituximab administration, we cannot assess whether rituximab not only blocks the acquisition of insulin antibodies induced by insulin administration and/or also suppresses preformed insulin autoantibodies. Studies in prediabetic non–insulin-treated patients will likely be needed to evaluate the specific effects of rituximab on levels of IAAs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
B-cell depletion with rituximab in relapsing-remitting multiple sclerosis
Hauser, S. L., Waubant, E., Arnold, D. L., Vollmer, T., Antel, J., Fox, R. J., Bar-Or, A., Panzara, M., Sarkar, N., Agarwal, S., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0706383 · Cited by 2,439
ISLET-CELL ANTIBODIES IN DIABETES MELLITUS WITH AUTOIMMUNE POLYENDOCRINE DEFICIENCIES
Bottazzo, G., Florin-Christensen, A., & Doniach, D. (1974) · The Lancet · doi:10.1016/s0140-6736(74)90140-8 · Cited by 1,469
Genetics, pathogenesis and clinical interventions in type 1 diabetes
Bluestone, J. A., Herold, K., & Eisenbarth, G. (2010) · Nature · doi:10.1038/nature08933 · Cited by 1,265 · cited 1×
“Type 1A, or immune-mediated, diabetes is believed to result from T-cell–mediated destruction of islet b-cells (6).”
BackgroundSelf-citationRituximab, B-lymphocyte depletion, and preservation of beta-cell function
Pescovitz, M. D., Greenbaum, C. J., Krause-Steinrauf, H., Becker, D. J., Gitelman, S. E., Goland, R., Gottlieb, P. A., Marks, J. B., McGee, P. F., Moran, A. M., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0904452 · Cited by 1,093
Self-citationInsulin antibodies in insulin-dependent diabetics before insulin treatment
Palmer, J. P., Asplin, C. M., Clemons, P., Lyen, K., Tatpati, O., Raghu, P. K., & Paquette, T. L. (1983) · Science · doi:10.1126/science.6362005 · Cited by 1,078
Pugliese, A., Zeller, M., Fernandez, A., Zalcberg, L. J., Bartlett, R. J., Ricordi, C., Pietropaolo, M., Eisenbarth, G. S., Bennett, S. T., & Patel, D. D. (1997) · Nature Genetics · doi:10.1038/ng0397-293 · Cited by 945
Self-citationInsulin expression in human thymus is modulated by INS VNTR alleles at the IDDM2 locus
Vafiadis, P., Bennett, S. T., Todd, J. A., Nadeau, J., Grabs, R., Goodyer, C. G., Wickramasinghe, S., Colle, E., & Polychronakos, C. (1997) · Nature Genetics · doi:10.1038/ng0397-289 · Cited by 809
Clinical Applications of Diabetes Antibody Testing
Bingley, P. J. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-1365 · Cited by 278 · cited 1×
“Type 1A, or autoimmune, diabetes is characterized by the presence of a series of autoantibodies targeting islet molecules, including insulin, GAD65, IA-2, and ZnT8 (15).”
BackgroundSteck, A. K., Johnson, K., Barriga, K. J., Miao, D., Yu, L., Hutton, J. C., Eisenbarth, G. S., & Rewers, M. J. (2011) · Diabetes Care · doi:10.2337/dc10-2088 · Cited by 195
Self-citation
Cited by
Type 1 diabetes: translating mechanistic observations into effective clinical outcomes
Herold, K. C., Vignali, D. A. A., Cooke, A., & Bluestone, J. A. (2013) · Nature Reviews Immunology · doi:10.1038/nri3422 · Cited by 237
Self-citationInsulin autoimmune syndrome: from diagnosis to clinical management
Censi, S., Mian, C., & Betterle, C. (2018) · Annals of Translational Medicine · doi:10.21037/atm.2018.07.32 · Cited by 152
Cappellani, D., Macchia, E., Falorni, A., & Marchetti, P. (2020) · Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy · doi:10.2147/dmso.s219438 · Cited by 138
MANAGEMENT OF ENDOCRINE DISEASE: Pathogenesis and management of hypoglycemia
Kittah, N. E., & Vella, A. (2017) · European Journal of Endocrinology · doi:10.1530/eje-16-1062 · Cited by 107
Two Cases of Methimazole-Induced Insulin Autoimmune Syndrome in Graves' Disease
Roh, E., Kim, Y. A., Ku, E. J., Bae, J. H., Kim, H. M., Cho, Y. M., Park, Y. J., Park, K. S., Kim, S. Y., & Kwak, S. H. (2013) · Endocrinology and Metabolism · doi:10.3803/enm.2013.28.1.55 · Cited by 24
Metadata
- Authors
- Yu, L., Herold, K., Krause-Steinrauf, H., McGee, P. L., Bundy, B., Pugliese, A., Krischer, J., Eisenbarth, G. S., & for the Type 1 Diabetes TrialNet Anti-CD20 Study Group
- Venue
- Diabetes
- Publisher
- American Diabetes Association
- Published
- 2011-09-16
- Volume
- 60
- Issue
- 10
- Pages
- 2560-2565
- ISSN
- 0012-1797 (ISSN-L)
- 1939-327X
- OpenAlex
- W2168300056
- Cited by
- 88
- References
- 9
- FWCI
- 4.93
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Rituximab Selectively Suppresses Specific Islet Antibodies. https://app.cochat.ai/papers/10.2337/db11-0674
- The paper
- Yu, L., Herold, K., Krause-Steinrauf, H., McGee, P. L., Bundy, B., Pugliese, A., Krischer, J., Eisenbarth, G. S., & for the Type 1 Diabetes TrialNet Anti-CD20 Study Group. (2011). Rituximab Selectively Suppresses Specific Islet Antibodies. Diabetes. https://doi.org/10.2337/db11-0674
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.